April 2018 article by CNBC.
While “gene therapy” treatments can offer tremendous benefits to patients and society, they limit the potential earnings for those investing in the technology. Curing patients means no recurring revenue, and in the case of infectious disease, shrinks the pool of new patients.
“Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.”
Read More
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
One Comment
recent posts
A new paper proposes a single ratio, read off a fingerprick, that tells you where your metabolism is headed. It started in a cancer clinic. Its authors think it belongs in every MetFix affiliate.
Mark Sisson separates longevity fads from the habits that consistently improve health and performance
Flawed scientific thinking lies at the heart of postmodern scientific, medical, and institutional failures
I like the efforts you have put in this, regards for all the great content.